Glaxo Zofran
Executive Summary
The company has no plans for additional studies of Zofran in alcoholism. Data from an investigator-initiated NIH trial of the anti-emetic ondansetron for the treatment of early-onset alcoholism was published in the Aug. 23 Journal of the American Medical Association. Glaxo issued a three page "fact sheet" coinciding with the JAMA publication, emphasizing that Zofran is not indicated for alcoholism. The investigator is planning a five-year study of 320 patients at the University of Texas Health Science Center, San Antonio. The alcoholism trials are using a very low dose of Zofran (4 mcg/kg) compounded from Glaxo's marketed tablets